CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Crizanlizumab +1 moredrug
Likely dose
Crizanlizumab 5.0 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04435184
NCT04435184Phase 2Completed
CompareCT.gov

Crizanlizumab for Treating COVID-19 Vasculopathy

Johns Hopkins University·interventional·Posted Jun 17, 2020·Updated Nov 9, 2021

In Brief

A Phase 2 clinical trial evaluating Crizanlizumab and 0.9% saline for COVID-19. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsNovartis, Socar Research SA, Brigham and Women's Hospital

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 17, 2020
Enrollment StartJul 9, 2020
Primary CompletionNov 28, 2020
Study CompletionJan 4, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.0 years ago

Interventions

Crizanlizumabdrug

Crizanlizumab 5.0 mg/kg in 100 ml IV once.

0.9% salineother

0.9% saline 100 ml IV once.